Medivation's MDV3100 Shown to Be Effective in a Preclinical Model of Hormone-Refractory Prostate Cancer

- Data Presented in Oral and Poster Presentations at ASCO's Prostate Cancer Symposium - 


SAN FRANCISCO, Feb. 26  /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that results from a preclinical study suggest that MDV3100, the Company's lead development candidate for hormone-refractory prostate cancer, is effective in a model of the disease.  The data were presented by Charles L. Sawyers, M.D., in an oral presentation (abstract #48) at the American Society of Clinical Oncology's (ASCO) Prostate Cancer Symposium in Orlando, Fla. during a session entitled "Imaging and Novel Therapeutics."

"All men who die of metastatic prostate cancer die from hormone-refractory disease," said Dr. Sawyers, chairman of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center in New York.  "While prostate cancer growth is driven by androgens like testosterone, current anti- androgen therapies do not stop the growth of hormone-refractory prostate tumors.  These preclinical findings with MDV3100 are extremely promising because MDV3100 not only dramatically inhibited the growth of otherwise refractory human prostate tumors, but in half of the cases the tumors regressed.  I am unaware of any other therapies that show similar effects in hormone-refractory prostate cancer."

Results of the research showed that MDV3100 treatment was associated with a significant dose-dependent reduction in tumor volume (p